PL4041733T3 - Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające - Google Patents
Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierająceInfo
- Publication number
- PL4041733T3 PL4041733T3 PL20887669.8T PL20887669T PL4041733T3 PL 4041733 T3 PL4041733 T3 PL 4041733T3 PL 20887669 T PL20887669 T PL 20887669T PL 4041733 T3 PL4041733 T3 PL 4041733T3
- Authority
- PL
- Poland
- Prior art keywords
- mountry
- dihydrobenzofuran
- indene
- dihydro
- derivatives
- Prior art date
Links
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 title 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190146679 | 2019-11-15 | ||
| PCT/KR2020/015864 WO2021096238A1 (en) | 2019-11-15 | 2020-11-12 | Novel derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4041733T3 true PL4041733T3 (pl) | 2024-09-23 |
Family
ID=75911374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20887669.8T PL4041733T3 (pl) | 2019-11-15 | 2020-11-12 | Pochodne mające ugrupowanie 2,3-dihydro-1h-indenu lub 2,3-dihydrobenzofuranu lub ich farmaceutycznie dopuszczalne sole oraz kompozycje farmaceutyczne je zawierające |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12522602B2 (pl) |
| EP (2) | EP4389744B8 (pl) |
| JP (2) | JP7671751B2 (pl) |
| KR (2) | KR102995744B1 (pl) |
| CN (2) | CN118955495A (pl) |
| AU (1) | AU2020384066B2 (pl) |
| BR (1) | BR112022009409A2 (pl) |
| CA (1) | CA3154313A1 (pl) |
| ES (2) | ES3058346T3 (pl) |
| MX (1) | MX2022005679A (pl) |
| PL (1) | PL4041733T3 (pl) |
| RS (1) | RS65662B1 (pl) |
| WO (1) | WO2021096238A1 (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| RS65576B1 (sr) | 2017-11-24 | 2024-06-28 | Jubilant Episcribe Llc | Heterociklična jedinjenja kao inhibitori prmt5 |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| WO2022240116A1 (en) * | 2021-05-11 | 2022-11-17 | Yuhan Corporation | Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same |
| TW202317546A (zh) | 2021-07-09 | 2023-05-01 | 美商普萊克斯姆公司 | 調節ikzf2之芳基化合物及醫藥組合物 |
| IL319915A (en) * | 2022-10-24 | 2025-05-01 | Yuhan Corp | Improved processes for the preparation of dimethyl-3,2-dihydro-1H-indene derivatives |
| KR20240057364A (ko) * | 2022-10-24 | 2024-05-02 | 주식회사유한양행 | 다이메틸-2,3-다이하이드로-1h-인덴 유도체의 신규 염 및 이의 제조방법 |
| WO2025032129A1 (en) | 2023-08-08 | 2025-02-13 | Syngenta Crop Protection Ag | Novel aminoindane and aminotetraline compounds |
| WO2025159544A1 (en) * | 2024-01-26 | 2025-07-31 | Yuhan Corporation | Pharmaceutical composition for preventing or treating gaucher disease |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| BRPI0517701A8 (pt) | 2004-11-10 | 2018-01-23 | Genzyme Corp | métodos de tratamento de diabetes mellitus |
| AU2008220056B2 (en) | 2007-02-28 | 2014-05-01 | Denka Company Limited | Reagent for quantitative determination of small, dense LDLs |
| EP2594565B1 (en) | 2007-05-31 | 2018-10-24 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| JP2011529500A (ja) | 2008-07-28 | 2011-12-08 | ジェンザイム コーポレーション | 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害 |
| WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| WO2010091164A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| LT2685986T (lt) | 2011-03-18 | 2020-03-10 | Genzyme Corporation | Gliukozilceramido sintazės slopiklis |
| US8961959B2 (en) | 2011-10-17 | 2015-02-24 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| CN110372636B (zh) | 2013-09-20 | 2023-03-28 | 生物马林药物股份有限公司 | 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂 |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| US10604514B2 (en) | 2017-10-19 | 2020-03-31 | Samumed, Llc | 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof |
| WO2019110521A1 (en) | 2017-12-04 | 2019-06-13 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Fluorophenyl substituted muscarinic receptor ligands with selectivity for m3 over m2 |
-
2020
- 2020-11-12 ES ES24163536T patent/ES3058346T3/es active Active
- 2020-11-12 RS RS20240700A patent/RS65662B1/sr unknown
- 2020-11-12 MX MX2022005679A patent/MX2022005679A/es unknown
- 2020-11-12 PL PL20887669.8T patent/PL4041733T3/pl unknown
- 2020-11-12 CA CA3154313A patent/CA3154313A1/en active Pending
- 2020-11-12 EP EP24163536.6A patent/EP4389744B8/en active Active
- 2020-11-12 EP EP20887669.8A patent/EP4041733B1/en active Active
- 2020-11-12 BR BR112022009409A patent/BR112022009409A2/pt unknown
- 2020-11-12 US US17/755,843 patent/US12522602B2/en active Active
- 2020-11-12 CN CN202410840972.5A patent/CN118955495A/zh active Pending
- 2020-11-12 CN CN202080075084.9A patent/CN114829361B/zh active Active
- 2020-11-12 AU AU2020384066A patent/AU2020384066B2/en active Active
- 2020-11-12 JP JP2022527911A patent/JP7671751B2/ja active Active
- 2020-11-12 ES ES20887669T patent/ES2984255T3/es active Active
- 2020-11-12 WO PCT/KR2020/015864 patent/WO2021096238A1/en not_active Ceased
- 2020-11-12 KR KR1020200150785A patent/KR102995744B1/ko active Active
-
2025
- 2025-04-21 JP JP2025069586A patent/JP7880463B2/ja active Active
- 2025-12-12 US US19/418,159 patent/US20260098038A1/en active Pending
-
2026
- 2026-07-21 KR KR1020260133359A patent/KR20260118374A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230002379A1 (en) | 2023-01-05 |
| CN114829361A (zh) | 2022-07-29 |
| JP7880463B2 (ja) | 2026-06-25 |
| EP4041733A1 (en) | 2022-08-17 |
| KR20260118374A (ko) | 2026-07-30 |
| RS65662B1 (sr) | 2024-07-31 |
| AU2020384066A1 (en) | 2022-04-21 |
| ES2984255T3 (es) | 2024-10-29 |
| JP2023503830A (ja) | 2023-02-01 |
| EP4389744B1 (en) | 2025-12-03 |
| MX2022005679A (es) | 2022-06-27 |
| US20260098038A1 (en) | 2026-04-09 |
| EP4041733C0 (en) | 2024-05-08 |
| ES3058346T3 (es) | 2026-03-10 |
| BR112022009409A2 (pt) | 2022-08-09 |
| AU2020384066B2 (en) | 2025-10-30 |
| KR20210059632A (ko) | 2021-05-25 |
| EP4041733B1 (en) | 2024-05-08 |
| CN114829361B (zh) | 2024-07-16 |
| US12522602B2 (en) | 2026-01-13 |
| EP4389744B8 (en) | 2026-08-12 |
| JP7671751B2 (ja) | 2025-05-02 |
| EP4389744A1 (en) | 2024-06-26 |
| KR102995744B1 (ko) | 2026-07-29 |
| WO2021096238A1 (en) | 2021-05-20 |
| EP4389744C0 (en) | 2025-12-03 |
| CN118955495A (zh) | 2024-11-15 |
| EP4041733A4 (en) | 2023-08-30 |
| JP2025111591A (ja) | 2025-07-30 |
| CA3154313A1 (en) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4041733C0 (en) | DERIVATIVES HAVING A 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN FRACTION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| DK3826632T3 (da) | Terapeutiske sammensætninger, der omfatter deutererede eller delvist deutererede n,n-dimethyltryptaminforbindelser | |
| EP4065640A4 (en) | NATURAL PACKAGING COMPOSITION | |
| GEAP202115066A (en) | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | |
| CY1119357T1 (el) | Φαρμακευτικες συνθεσεις που περιλαμβανουν συνδετες υποδοχεων σιγμα | |
| IL285739B2 (en) | Crystalline Form A of Hydrochloride Salt of (S)-(4,5-DIHYDRO-7H-THIENO[3,2c]PYRAN-7YL)-N-METHYLMETHANAMINE HCL and Related Pharmaceutical Preparations | |
| HRP20240643T1 (hr) | Heterociklički spojevi za inhibiciju aktivnosti tyk2 | |
| DK3999038T3 (da) | Orale formuleringer af en kardial sarcomer-inhibitor | |
| EP4041734C0 (en) | DERIVATIVES HAVING A 1,2,3,4-TETRAHYDRONAPHTHALENE FRACTION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | |
| BR112017020081A2 (pt) | análogos deuterados de etifoxina, seus derivados e usos dos mesmos | |
| EP4221690A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| EP3947172A4 (en) | PACKAGING STRUCTURES | |
| MX2017013678A (es) | Derivados heterociclicos de seis miembros y composicion farmaceutica que los comprende. | |
| EP3993782A4 (en) | DELAYED-RELEASE ENDOXIDE COMPOSITIONS | |
| DK3897589T3 (da) | Farmaceutiske formuleringer indeholdende relacorilant, en heteroaryl-ketonkondenseret azadecalinforbindelse | |
| EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
| EP3914362C0 (en) | Exercise machine | |
| JOP20170197A1 (ar) | الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول | |
| EP3917926A4 (en) | IMIDAZOCHINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, USE THEREOF | |
| EP4135699A4 (en) | Pharmaceutical compositions | |
| CO2020011860A2 (es) | Compuestos de 4–metildihidropirimidinona y su uso farmacéutico | |
| BR112022007207A2 (pt) | Composição farmacêutica que compreende selexipag | |
| KR102474935B9 (ko) | 파에오놀 및 판테놀 또는 이들의 약학적으로 허용가능한 염을 유효성분으로 포함하는 약학적 조성물 |